HR. 1117In Committee
Responsibility in Drug Advertising Act of 2025
Prohibits direct to consumer advertising for newly approved drugs for three years after FDA approval, with limited FDA waiver and extension authority
Plain-English overview
What this bill does
Prohibits direct to consumer advertising for newly approved drugs for three years after FDA approval, with limited FDA waiver and extension authority
Key points
- Prohibit new drug advertising
- Allow FDA waivers
- Allow extended advertising bans
Current status
Where it stands
Status
In Committee
Latest action
2025-02-07 — Referred to the House Committee on Energy and Commerce.
Related context
Topics and policy areas
undefinedBroadcasting, cable, digital technologiesDrug safety, medical device, and laboratory regulationHealthInternet, web applications, social mediaMarketing and advertisingPrescription drugs